MA56019A - Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies - Google Patents

Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies

Info

Publication number
MA56019A
MA56019A MA056019A MA56019A MA56019A MA 56019 A MA56019 A MA 56019A MA 056019 A MA056019 A MA 056019A MA 56019 A MA56019 A MA 56019A MA 56019 A MA56019 A MA 56019A
Authority
MA
Morocco
Prior art keywords
diseases
treatment
pharmaceutical compositions
new compounds
related pharmaceutical
Prior art date
Application number
MA056019A
Other languages
English (en)
Inventor
Luke Jonathan Alvey
Florence Marie-Emilie Bonnaterre
Denis Bucher
Nicolas Desroy
Béranger Duthion
Hélène Marie Jary
Christophe Peixoto
Taoues Temal-Laïb
Amynata Tirera
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA56019A publication Critical patent/MA56019A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA056019A 2019-05-29 2020-05-25 Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies MA56019A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1907616.5A GB201907616D0 (en) 2019-05-29 2019-05-29 Novel compounds and pharmaceutical compositons thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
MA56019A true MA56019A (fr) 2022-04-06

Family

ID=67385363

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056019A MA56019A (fr) 2019-05-29 2020-05-25 Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies

Country Status (26)

Country Link
US (1) US12391679B2 (fr)
EP (1) EP3976189B1 (fr)
JP (1) JP7550174B2 (fr)
KR (1) KR102959382B1 (fr)
CN (1) CN113924146B (fr)
AR (1) AR119028A1 (fr)
AU (1) AU2020281650B2 (fr)
BR (1) BR112021023900A2 (fr)
CA (1) CA3141683A1 (fr)
CL (1) CL2021003133A1 (fr)
CO (1) CO2021017656A2 (fr)
CR (1) CR20210586A (fr)
DO (1) DOP2021000227A (fr)
EA (1) EA202193281A1 (fr)
ES (1) ES2985528T3 (fr)
GB (1) GB201907616D0 (fr)
IL (1) IL288375B2 (fr)
MA (1) MA56019A (fr)
MX (1) MX2021013803A (fr)
PE (1) PE20220503A1 (fr)
PH (1) PH12021552691A1 (fr)
PL (1) PL3976189T3 (fr)
SG (1) SG11202112652RA (fr)
TW (1) TW202110839A (fr)
WO (1) WO2020239658A1 (fr)
ZA (1) ZA202110597B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
CN113784955B (zh) 2019-03-11 2025-02-14 因弗拉克斯有限责任公司 作为C5a受体调节剂的稠合哌啶基双环和相关化合物
GB201907558D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
BR112023001952A2 (pt) * 2020-08-05 2023-02-28 Massachusetts Gen Hospital Inibidores de quinase induzíveis por sal
CN115197208A (zh) * 2021-04-01 2022-10-18 江苏恒瑞医药股份有限公司 杂芳基类化合物、其制备方法及其在医药上的应用
USD982434S1 (en) * 2021-08-31 2023-04-04 Level Up Dice LLC Dice storage container
WO2023066204A1 (fr) * 2021-10-18 2023-04-27 上海美悦生物科技发展有限公司 Inhibiteur de sik, composition de celui-ci, son procédé de préparation et son utilisation
AR128279A1 (es) * 2022-01-19 2024-04-10 Hoffmann La Roche Nuevos derivados de bencimidazol piridina
CN115304605B (zh) * 2022-01-21 2023-10-03 陕西国际商贸学院 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用
EP4547663A1 (fr) * 2022-07-01 2025-05-07 F. Hoffmann-La Roche AG Dérivés d'imidazo [4,5-c] pyridine en tant que modulateurs de sik pour le traitement de la polyarthrite rhumatoïde
US20240124450A1 (en) * 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2024104441A1 (fr) * 2022-11-17 2024-05-23 Insilico Medicine Ip Limited Inhibiteurs de kinases inductibles par sel (sik) et leurs procédés d'utilisation
IL324835A (en) 2023-05-24 2026-01-01 Mitsubishi Tanabe Pharma Corp Salt-inducible kinase inhibitory compound and pharmaceutical composition containing same
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
WO2025017043A1 (fr) * 2023-07-19 2025-01-23 F. Hoffmann-La Roche Ag Nouveaux dérivés de benzimidazole pyridine
AU2024352869A1 (en) * 2023-09-26 2026-04-09 Onco3R Therapeutics Bv Compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2025232877A1 (fr) * 2024-05-10 2025-11-13 Insilico Medicine Ip Limited Inhibiteurs de kinases inductibles au sel (sik)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461162B2 (en) * 2007-07-20 2013-06-11 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives
WO2012068406A2 (fr) 2010-11-18 2012-05-24 Ligand Pharmaceuticals Incorporated Utilisation de mimétiques d'un facteur de croissance hématopoïétique
WO2012075252A1 (fr) 2010-12-01 2012-06-07 Plasan Carbon Composites, Inc. Procédé et système permettant de former des articles composites
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾピリダジン
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
JP2018526452A (ja) 2015-09-03 2018-09-13 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Dyrk1aの小分子抑制剤およびその使用
CN106496222A (zh) 2016-09-07 2017-03-15 华东师范大学 一种咪唑并[1,2‑a]吡啶化合物及其制备方法和应用
PH12020550725B1 (en) 2017-12-02 2024-05-24 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
CN108358894B (zh) * 2018-04-26 2021-05-07 四川大学 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用
CA3103304A1 (fr) 2018-06-15 2019-12-19 Galapagos Nv Nouveaux composes et compositions pharmaceutiques associees pour le traitement de maladies
CN118684661A (zh) 2023-03-21 2024-09-24 上海美悦生物科技发展有限公司 杂芳基类化合物及其药物组合物、制备方法和用途

Also Published As

Publication number Publication date
CA3141683A1 (fr) 2020-12-03
ZA202110597B (en) 2024-10-30
CN113924146B (zh) 2024-12-10
IL288375B1 (en) 2025-09-01
BR112021023900A2 (pt) 2022-01-18
CO2021017656A2 (es) 2022-01-17
TW202110839A (zh) 2021-03-16
EP3976189C0 (fr) 2024-07-03
WO2020239658A1 (fr) 2020-12-03
AU2020281650B2 (en) 2025-08-28
MX2021013803A (es) 2021-12-14
CL2021003133A1 (es) 2022-07-22
EA202193281A1 (ru) 2022-03-01
CN113924146A (zh) 2022-01-11
ES2985528T3 (es) 2024-11-06
IL288375B2 (en) 2026-01-01
JP7550174B2 (ja) 2024-09-12
AR119028A1 (es) 2021-11-17
DOP2021000227A (es) 2022-05-15
AU2020281650A1 (en) 2022-02-03
KR20220015450A (ko) 2022-02-08
PH12021552691A1 (en) 2022-03-14
CR20210586A (es) 2022-01-24
US20220340548A1 (en) 2022-10-27
PL3976189T3 (pl) 2024-09-09
US12391679B2 (en) 2025-08-19
PE20220503A1 (es) 2022-04-07
EP3976189B1 (fr) 2024-07-03
EP3976189A1 (fr) 2022-04-06
GB201907616D0 (en) 2019-07-10
SG11202112652RA (en) 2021-12-30
IL288375A (en) 2022-01-01
JP2022534578A (ja) 2022-08-02
KR102959382B1 (ko) 2026-04-30

Similar Documents

Publication Publication Date Title
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
EP3968996A4 (fr) Composés triaryles pour le traitement de maladies pd-l1
EP3866781A4 (fr) Nouvelles compositions pour le traitement de maladies inflammatoires
EP4045037C0 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
EP3890747A4 (fr) Compositions pour le traitement de la fibrose et de l'inflammation
MA55497A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
ZA202110597B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
MA52118A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3937932A4 (fr) Inhibiteurs de cgaz pour le traitement de maladies auto-inflammatoires et de métastases cancéreuses
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
EP4045036A4 (fr) Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1
EP3621973A4 (fr) Composés pour la prévention et le traitement de maladies et leur utilisation
EP3829569A4 (fr) Formulations de spinosyne pour le traitement de maladies oculaires et faciaux provoquées par demodex
EP3841086A4 (fr) Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
EP3661553A4 (fr) Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes
EP3639833A4 (fr) Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l'inflammation
EP3877383A4 (fr) Composés et compositions pour le traitement de maladies respiratoires
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
MA55982A (fr) Composition pharmaceutique pour le traitement de tumeurs
EP3936124A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies neurologiques